Trifarotene

Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris.[5][6] It is a retinoid;[5][7] more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist.[8]

Trifarotene
Clinical data
Trade namesAklief
Other namesCD5789
AHFS/Drugs.comMonograph
MedlinePlusa620004
License data
Pregnancy
category
Routes of
administration		Topical
Drug classSkin and mucous membrane agents
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • 4-[3-(3-tert-Butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.278.901
Chemical and physical data
FormulaC29H33NO4
Molar mass459.586 g·mol−1
3D model (JSmol)
SMILES
  • CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
InChI
  • InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
  • Key:MFBCDACCJCDGBA-UHFFFAOYSA-N

Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[9][10] It was approved for medical use in the United States in October 2019.[6][11][12] In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.[13]

Medical uses

In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.[5]

In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older.[1][2][3]

Society and culture

Trifarotene was approved for medical use in the United States in October 2019,[12] in Canada in November 2019,[3] and in Australia in January 2021.[1][2]

References
  1. "Trifarotene Product Information". Therapeutic Goods Administration (TGA). Retrieved 23 May 2021.
  2. "Aklief". Therapeutic Goods Administration (TGA). 28 January 2021. Retrieved 8 September 2021.
  3. https://pdf.hres.ca/dpd_pm/00054047.PDF
  4. "Summary Basis of Decision (SBD) for Aklief". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  5. "Aklief- trifarotene cream". DailyMed. Retrieved 22 May 2021.
  6. "Drug Trials Snapshots: Aklief". U.S. Food and Drug Administration (FDA). 11 October 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019. This article incorporates text from this source, which is in the public domain.
  7. "Trifarotene Monograph for Professionals". Drugs.com. 28 October 2019. Retrieved 23 May 2021.
  8. Scott LJ (November 2019). "Trifarotene: First Approval". Drugs. 79 (17): 1905–09. doi:10.1007/s40265-019-01218-6. PMID 31713811. S2CID 207964653.
  9. "Trifarotene Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 19 August 2020.
  10. "EU/3/20/2264". European Medicines Agency (EMA). 12 August 2020. Retrieved 19 August 2020.
  11. "Aklief (trifarotene) FDA Approval History". Drugs.com. 7 October 2019. Retrieved 19 November 2019.
  12. "Drug Approval Package: Aklief". U.S. Food and Drug Administration (FDA). 21 October 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019.
  13. "Galderma receives a positive outcome through the European Decentralised Procedure for AKLIEF (trifarotene 50 mcg/g cream), the first new retinoid molecule for acne in the European Union in 25 years" (Press release). Galderma. 20 December 2019 – via Business Wire.
  • "Trifarotene". Drug Information Portal. U.S. National Library of Medicine (NLM).


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.